Related Experiment Video
Updated: Jun 12, 2025
Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia
Published on: June 28, 2018
Risk factors and outcomes of inadequate empirical antibiotic therapy in ventilator-associated pneumonia: a systematic
Alina Tariq1, Theodosios Kantas2, Bundhoo Beebee Shabneeze3
1Larkin Community Hospital Global Research Program, South Miami, Florida, USA.
Objectives:
Inadequate empirical antibiotic therapy for ventilator-associated pneumonia (VAP) is defined as at least one bacterial isolate not covered by initial antibiotics, or when the bacteria were resistant to all empiric antibiotics. The aim of our study is to identify the associated risk factors and outcomes of inadequately treated VAP in critically ill adults.
Methods:
PubMed, Embase, and Google Scholar databases were systematically searched until March 2024. Any observational study reporting on inadequate antibiotic therapy of adult patients (≥18 years) admitted to the intensive care unit (ICU) with a diagnosis of VAP was included in the analysis. The risk factors studied in this meta-analysis were isolation of multi-drug resistant (MDR) bacteria, prior use of antibiotics, admission in surgical units, polymicrobial infection, and late-onset VAP. Likewise, outcomes like in-hospital mortality, length of stay in the ICU and hospital, and duration of intubation were also studied.
Results:
Isolation of MDR bacteria from the patient significantly increased the risk of inadequate empirical antibiotic treatment (OR = 2.50, 95% C.I. = 1.57-3.97, P < 0.016). Prior use of antibiotics, admission in surgical units, polymicrobial infection, and late-onset VAP were not associated with the inadequate treatment. Likewise, inadequately treated VAP had significantly higher in-hospital mortality (RR = 1.66, 95% C.I. = 1.23-2.23, P < 0.001) and intubation duration (HG = 0.31, 95% C.I. = 0.03-0.59, P = 0.03) as compared to patients who received adequate treatment.
Conclusions:
VAP caused by MDR pathogens were highly likely to receive inadequate empirical antibiotic therapy. The mortality rate and intubation duration were significantly longer in inadequately treated VAP as compared to adequately treated VAP.
Insights
Inadequate antibiotic therapy for ventilator-associated pneumonia (VAP) is linked to multi-drug resistant (MDR) bacteria. This leads to higher mortality and longer intubation times in critically ill patients.
Area of Science:
- Critical Care Medicine
- Infectious Diseases
- Pharmacology
Background:
- Ventilator-associated pneumonia (VAP) poses significant challenges in intensive care units (ICUs).
- Inadequate empirical antibiotic therapy is a critical concern, potentially leading to adverse outcomes.
- Identifying risk factors and consequences of undertreated VAP is crucial for improving patient management.
Purpose of the Study:
- To identify risk factors associated with inadequate empirical antibiotic therapy in adult patients with VAP.
- To determine the outcomes of inadequately treated VAP in critically ill adults.
Main Methods:
- A systematic meta-analysis was conducted, searching PubMed, Embase, and Google Scholar until March 2024.
- Included observational studies of adult patients (≥18 years) diagnosed with VAP in the ICU.
- Risk factors and outcomes such as multi-drug resistant (MDR) bacteria, prior antibiotic use, mortality, and intubation duration were analyzed.
Main Results:
- Isolation of MDR bacteria significantly increased the risk of inadequate empirical antibiotic treatment (OR = 2.50).
- Inadequately treated VAP was associated with significantly higher in-hospital mortality (RR = 1.66) and longer intubation duration (HG = 0.31).
- Prior antibiotic use, surgical unit admission, polymicrobial infection, and late-onset VAP were not significantly associated with inadequate treatment.
Conclusions:
- Ventilator-associated pneumonia caused by MDR pathogens is highly likely to receive inadequate empirical antibiotic therapy.
- Inadequately treated VAP results in significantly increased mortality rates and prolonged intubation durations compared to adequately treated VAP.
More Related Videos
09:26Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Related Concept Videos
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia III: Complications and Assessment
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:29Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...